공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

아나필락시스 : 파이프라인 리뷰

Anaphylaxis (Immunology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 360911
페이지 정보 영문 67 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


아나필락시스 : 파이프라인 리뷰 Anaphylaxis (Immunology) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 67 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

아나필락시스는 생명을 위협하는 위험성이 있는 알레르기 반응입니다. 증상에는 현기증, 오심·구토, 설사, 열감, 기도 협착, 혀나 목의 붓기 등이 있습니다. 위험요인으로서 아나필락시스, 알레르기, 천식의 개인력, 가족력이 있습니다. 치료에는 베타 작용제, 항히스타민제, 코르치존 등을 사용합니다.

아나필락시스(Anaphylaxis) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 주요 치료제 개발 참여 기업 및 약제 개요, 최신 파이프라인 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

아나필락시스 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관에서 개발된 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Adamis Pharmaceuticals Corp
  • MannKind Corp
  • Monosol Rx LLC

약제 프로파일

휴지 상태인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.07.31

List of Tables

List of Tables

  • Number of Products under Development for Anaphylaxis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2021
  • Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2021
  • Anaphylaxis - Pipeline by BioArdis LLC, 2021
  • Anaphylaxis - Pipeline by Bryn Pharma LLC, 2021
  • Anaphylaxis - Pipeline by G2B Pharma Inc, 2021
  • Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2021
  • Anaphylaxis - Pipeline by JDP Therapeutics Inc, 2021
  • Anaphylaxis - Pipeline by MannKind Corp, 2021
  • Anaphylaxis - Pipeline by Merck & Co Inc, 2021
  • Anaphylaxis - Pipeline by Pharmacin BV, 2021
  • Anaphylaxis - Pipeline by PIMS-E, 2021
  • Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, 2021
  • Anaphylaxis - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Anaphylaxis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Drugs In Development, 2021, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Anaphylaxis - Overview
  • Anaphylaxis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Anaphylaxis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Anaphylaxis - Companies Involved in Therapeutics Development
  • Aquestive Therapeutics Inc
  • ARS Pharmaceuticals Inc
  • BioArdis LLC
  • Bryn Pharma LLC
  • G2B Pharma Inc
  • Hoth Therapeutics Inc
  • JDP Therapeutics Inc
  • MannKind Corp
  • Merck & Co Inc
  • Pharmacin BV
  • PIMS-E
  • Shenox Pharmaceuticals LLC
  • Anaphylaxis - Drug Profiles
  • AQST-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • epinephrine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HLK-0006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HT-KIT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JDP-207 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHX-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize MRGPRX2 for Anaphylaxis, Asthma, Inflammation and Pruritus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XL-499 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Anaphylaxis - Dormant Projects
  • Anaphylaxis - Product Development Milestones
  • Featured News & Press Releases
  • Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-109 at R&D event
  • Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-108 at R&D event
  • Mar 05, 2021: Aquestive Therapeutics to host investor & analyst virtual epinephrine drug delivery R&D event on March 25 at 9:00 a.m. ET
  • Nov 30, 2020: Recordati: Market authorization application for ARS-1 (epinephrine nasal spray) accepted by European Medicines Agency
  • Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral anaphylaxis treatment
  • Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including anaphylaxis
  • Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including anaphylaxis
  • Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine nasal spray)
  • Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for anaphylaxis treatment
  • Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intranasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Journals
  • May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
  • Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults
  • Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
  • Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment
  • Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q